Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

Johnson and Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and ...

Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...